Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
12.02 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Rocket Pharmaceuticals, Inc. |
Symbool | RCKT |
Munteenheid | USD |
Prijs | 12.02 |
Beurswaarde | 1,278,170,740 |
Dividendpercentage | 0% |
52-weken bereik | 11.15 - 32.525 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gaurav D. Shah M.D. |
Website | https://rocketpharma.com |
An error occurred while fetching data.
Over Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)